Biotech company Biogen lowered its full-year profit forecast, citing higher costs related to its purchase of drug maker Reata Pharmaceuticals as well as the launch of its Alzheimer's drug.
A new CEO takes over the embattled planemaker. Plus: Elon picks a fight, the Fed might finally cut rates and Microsoft makes a lot of money but not enough.
Will the exercising at home revolution continue in a post-Covid world? Find out what the FlexIt CEO had to say, plus the company's partnership with TalkSpace.